{"id":"bax855","safety":{"commonSideEffects":[{"rate":null,"effect":"Inhibitor development (factor VIII antibodies)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BAX855 replaces deficient or dysfunctional factor VIII, a critical clotting factor, allowing patients with hemophilia A to form stable blood clots. The Fc fusion extends the drug's circulating half-life compared to conventional factor VIII products, potentially reducing dosing frequency. This enables better sustained factor VIII activity and improved hemostatic control.","oneSentence":"BAX855 is a recombinant factor VIII (antihemophilic factor) fused to the Fc portion of human immunoglobulin G1 to extend half-life and improve hemostasis in hemophilia A.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:36.917Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hemophilia A (on-demand and prophylactic treatment)"}]},"trialDetails":[{"nctId":"NCT04158934","phase":"","title":"A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baxalta now part of Shire","startDate":"2020-07-09","conditions":"Hemophilia A","enrollment":207},{"nctId":"NCT05042440","phase":"PHASE1","title":"Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-08-11","conditions":"Hemophilia A","enrollment":13},{"nctId":"NCT02615691","phase":"PHASE3","title":"A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2015-11-12","conditions":"Hemophilia A","enrollment":120},{"nctId":"NCT05707351","phase":"PHASE3","title":"A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-03-27","conditions":"Hemophilia A","enrollment":37},{"nctId":"NCT04690322","phase":"PHASE4","title":"POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2021-04-15","conditions":"Hemophilia A, Factor VIII","enrollment":28},{"nctId":"NCT03169972","phase":"","title":"ADYNOVATE Drug Use-Results Survey","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-02-01","conditions":"Hemophilia A","enrollment":135},{"nctId":"NCT04941898","phase":"","title":"A Study of TAK-660 in Surgical Procedures for People With Hemophilia A.","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-06-30","conditions":"Hemophilia A","enrollment":16},{"nctId":"NCT02078427","phase":"","title":"ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2011-06-28","conditions":"Hemophilia A","enrollment":951},{"nctId":"NCT03824522","phase":"","title":"Post Marketing Surveillance Study for ADYNOVATE in South Korea","status":"COMPLETED","sponsor":"Takeda","startDate":"2019-02-25","conditions":"Hemophilia A","enrollment":341},{"nctId":"NCT03006965","phase":"","title":"Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT®","status":"COMPLETED","sponsor":"Spanish Society of Thrombosis and Haemostasis","startDate":"2016-11-11","conditions":"Hemophilia A, Hemophilia, Factor VIII Deficiency","enrollment":50},{"nctId":"NCT02546622","phase":"","title":"ATHN 2: Factor Switching Study","status":"COMPLETED","sponsor":"American Thrombosis and Hemostasis Network","startDate":"2015-09","conditions":"Hemophilia","enrollment":310},{"nctId":"NCT02585960","phase":"PHASE3","title":"BAX 855 PK-guided Dosing","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2015-11-23","conditions":"Hemophilia A","enrollment":135},{"nctId":"NCT01913405","phase":"PHASE3","title":"Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2013-12-20","conditions":"Hemophilia A","enrollment":30},{"nctId":"NCT02210091","phase":"PHASE3","title":"BAX 855 Pediatric Study","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2014-10-31","conditions":"Hemophilia A","enrollment":75},{"nctId":"NCT01945593","phase":"PHASE3","title":"BAX 855 Continuation","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2013-10-15","conditions":"Hemophilia A","enrollment":218},{"nctId":"NCT01736475","phase":"PHASE2, PHASE3","title":"Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2013-01-31","conditions":"Hemophilia A","enrollment":159},{"nctId":"NCT01599819","phase":"PHASE1","title":"BAX 855 Dose-Escalation Safety Study","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2011-09-30","conditions":"Hemophilia A","enrollment":19},{"nctId":"NCT04015492","phase":"PHASE1","title":"Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII)","status":"COMPLETED","sponsor":"Bayer","startDate":"2019-08-08","conditions":"Hemophilia A","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ADYNOVATE","BAX 855","PEGylated Recombinant Factor VIII"],"phase":"phase_3","status":"active","brandName":"BAX855","genericName":"BAX855","companyName":"Baxalta now part of Shire","companyId":"baxalta-now-part-of-shire","modality":"Biologic","firstApprovalDate":"","aiSummary":"BAX855 is a recombinant factor VIII (antihemophilic factor) fused to the Fc portion of human immunoglobulin G1 to extend half-life and improve hemostasis in hemophilia A. Used for Hemophilia A (on-demand and prophylactic treatment).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}